Benzinga · Nov 19, 2026
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.

